CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
odronextamab 在 2 例对 CAR-T 细胞疗法耐药的弥漫大 B 细胞淋巴瘤患者中达到完全缓解
英文原题：Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
查看英文原题
Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
对于复发/难治性B细胞非霍奇金淋巴瘤（R/R B-NHL）患者，结局仍然不佳。虽然嵌合抗原受体（CAR）T细胞疗法已经彻底改变了治疗方式，但仍有相当比例的患者复发或未能应答。Odronextamab是一种CD20 CD3双特异性抗体，在首次人体试验（NCT02290951）中，已在R/R B-NHL患者中显示出持久应答和可控的安全性特征。在此，我们记录了2例对CAR-T 细胞疗法难治的弥漫性大B细胞淋巴瘤患者。两例患者在接受odronextamab后均获得完全缓解，且缓解持续2年。两例患者在治疗期间均未发生3级细胞因子释放综合征或3级神经系统不良事件。
展开英文摘要原文
Outcomes remain poor for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). While chimeric antigen receptor (CAR) T-cell therapy has revolutionised treatment, a significant proportion of patients relapse or fail to respond. Odronextamab is a CD20 CD3 bispecific antibody that has demonstrated durable responses and a manageable safety profile in patients with R/R B-NHL in a first-in-human trial (NCT02290951).
Here, we document two patients with diffuse large B-cell lymphoma refractory to CART-cell therapy. Both achieved complete responses that remain ongoing for 2 years following odronextamab. Neither patient experienced Grade 3 cytokine release syndrome or Grade 3 neurological adverse events during treatment.
论文信息
- 作者
- Weinstock M、Elavalakanar P、Bright S、Ambati SR、Brouwer-Visser J、Pourpe S、Fiaschi N、Jankovic V
- 单位
- Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.Israel
- 文献类型
- 病例报告 · 非美国政府资助研究
- 期刊
- British journal of haematology2022 Nov
- 原文标识
- PubMed 35892294 · DOI 10.1111/bjh.18383
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →